Amgen Inc. (AMGN) Nasdaq Global Select
193.201.130.59%
IEX real time price11:08:14 AM

News: updated – 17-Dec 11:09


Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration17-Dec 09:00(PR Newswire)

THOUSAND OAKS, Calif. , Dec. 17, 2018 /PRNewswire/ –Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE (infliximab). "At Amgen, we have…

Teva up 1% premarket on positive fremanezumab data17-Dec 08:38(SeekingAlpha)

Teva Pharmaceutical Industries (NYSE: TEVA ) is up 1% premarket on modest volume in response to its announcement of positive results from a Phase 3 clinical trial, FOCUS , evaluating fremanezumab in adults with chronic or episodic migraine. More news on: Teva Pharmaceutical …